» Articles » PMID: 32089742

Association of MRI-derived Radiomic Biomarker with Disease-free Survival in Patients with Early-stage Cervical Cancer

Overview
Journal Theranostics
Date 2020 Feb 25
PMID 32089742
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Pre-treatment survival prediction plays a key role in many diseases. We aimed to determine the prognostic value of pre-treatment Magnetic Resonance Imaging (MRI) based radiomic score for disease-free survival (DFS) in patients with early-stage (IB-IIA) cervical cancer. A total of 248 patients with early-stage cervical cancer underwent radical hysterectomy were included from two institutions between January 1, 2011 and December 31, 2017, whose MR imaging data, clinicopathological data and DFS data were collected. Patients data were randomly divided into the training cohort (n = 166) and the validation cohort (n=82). Radiomic features were extracted from the pre-treatment T2-weighted (T2w) and contrast-enhanced T1-weighted (CET1w) MR imagings for each patient. Least absolute shrinkage and selection operator (LASSO) regression and Cox proportional hazard model were applied to construct radiomic score (Rad-score). According to the cutoff of Rad-score, patients were divided into low- and high- risk groups. Pearson's correlation and Kaplan-Meier analysis were used to evaluate the association of Rad-score with DFS. A combined model incorporating Rad-score, lymph node metastasis (LNM) and lymphovascular space invasion (LVI) by multivariate Cox proportional hazard model was constructed to estimate DFS individually. Higher Rad-scores were significantly associated with worse DFS in the training and validation cohorts (<0.001 and =0.011, respectively). The Rad-score demonstrated better prognostic performance in estimating DFS (C-index, 0.753; 95% CI: 0.696-0.805) than the clinicopathological features (C-index, 0.632; 95% CI: 0.567-0.700). However, the combined model showed no significant improvement (C-index, 0.714; 95%CI: 0.642-0.784). The results demonstrated that MRI-derived Rad-score can be used as a prognostic biomarker for patients with early-stage (IB-IIA) cervical cancer, which can facilitate clinical decision-making.

Citing Articles

MRI-based deep learning radiomics to differentiate dual-phenotype hepatocellular carcinoma from HCC and intrahepatic cholangiocarcinoma: a multicenter study.

Wu Q, Zhang T, Xu F, Cao L, Gu W, Zhu W Insights Imaging. 2025; 16(1):27.

PMID: 39881111 PMC: 11780023. DOI: 10.1186/s13244-025-01904-y.


Pre-treatment T2-weighted magnetic resonance radiomics for prediction of loco-regional recurrence after image-guided adaptive brachytherapy for locally advanced cervical cancer.

Dankulchai P, Thanamitsomboon N, Sittiwong W, Kosaisawe N, Thephamongkhol K, Phongprapun W J Contemp Brachytherapy. 2024; 16(3):193-201.

PMID: 39629090 PMC: 11609862. DOI: 10.5114/jcb.2024.141458.


Bibliometric and visual analysis of radiomics for evaluating lymph node status in oncology.

Lyu G, Tong T, Yang G, Zhao J, Xu Z, Zheng N Front Med (Lausanne). 2024; 11:1501652.

PMID: 39610679 PMC: 11602298. DOI: 10.3389/fmed.2024.1501652.


Prognostic Factors for Cervical Cancer in Asian Populations: A Scoping Review of Research From 2013 to 2023.

Abrar S, Azmel Mohd Isa S, Mohd Hairon S, Yaacob N, Ismail M Cureus. 2024; 16(10):e71359.

PMID: 39534844 PMC: 11556266. DOI: 10.7759/cureus.71359.


Development and validation of radiomic signature for predicting overall survival in advanced-stage cervical cancer.

Jha A, Mithun S, Sherkhane U, Jaiswar V, Shah S, Purandare N Front Nucl Med. 2024; 3:1138552.

PMID: 39355056 PMC: 11440856. DOI: 10.3389/fnume.2023.1138552.


References
1.
Ho C, Chien T, Huang S, Wu C, Shih B, Chang S . Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol. 2004; 93(2):458-64. DOI: 10.1016/j.ygyno.2004.01.026. View

2.
Liu Z, Zhang X, Shi Y, Wang L, Zhu H, Tang Z . Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Clin Cancer Res. 2017; 23(23):7253-7262. DOI: 10.1158/1078-0432.CCR-17-1038. View

3.
Quinn M, Benedet J, Odicino F, Maisonneuve P, Beller U, Creasman W . Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1:S43-103. DOI: 10.1016/S0020-7292(06)60030-1. View

4.
Sun C, Tian X, Liu Z, Li W, Li P, Chen J . Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: A multicentre study. EBioMedicine. 2019; 46:160-169. PMC: 6712288. DOI: 10.1016/j.ebiom.2019.07.049. View

5.
Chung H, Kang S, Ha S, Kim J, Park N, Song Y . Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer. J Gynecol Oncol. 2016; 27(2):e15. PMC: 4717220. DOI: 10.3802/jgo.2016.27.e15. View